Clinical trials: Stomach Disorders
Hypoglycemia, Evidence of Previous Gastric Surgery
Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery
The purpose of this study is to determine whether pramlintide (Symlin) will help to reduce the frequency and severity of hypoglycemia in individuals who have had gastric bypass surgery.
- Trial name
- NCT01841359
- Testing
- Pramlintide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Joslin Diabetes Center
Obesity
Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery
This is a randomized, double-blinded, placebo-controlled trial of liraglutide versus placebo over a follow-up period of 12 months in patients at least 18 months following Roux-en-Y gastric bypass (RYGB) who are experiencing…
- Trial name
- NCT03048578
- Testing
- Saxenda
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- NYU Langone Health
Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma
Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
This phase I/II trial studies the side effects and best dose of olaparib when given together with ramucirumab and how well they work in treating patients with gastric or gastroesophageal junction cancer that has spread to other…
- Conditions
- Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Carcinoma
- Trial name
- NCT03008278
- Testing
- Olaparib, Ramucirumab
- Where
- 32 sites in United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Gastroparesis
Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States. One hundred fifty (150) subjects diagnosed with gastroparesis, who satisfy the selection criteria for the study, will…
- Trial name
- NCT02970968
- Testing
- VLY-686 (Tradipitant)
- Where
- 38 sites in United States
- Volunteers
- 152 people
- Sponsor
- Vanda Pharmaceuticals
Esophageal Cancer, Gastric Cancer
Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer
Cetuximab, Paclitaxel, Carboplatin and Radiation for Esophageal, Gastroesophageal Junction and Gastric Cancer
- Trial name
- NCT00439608
- Testing
- Cetuximab,Paclitaxel, Carboplatin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Brown University
Stage T3-4NxM0 Gastric Cancer
Neo-adjuvant Chemotherapy in Locally Advanced Gastric Cancer
Thymidylate Synthase (TS) is a key enzyme in the synthesis of DNA and the target enzyme inhibited by 5-fluorouracil (5-FU). TS level in the tumour cells has been reported as predictive to response to 5-FU and a prognostic factor…
- Trial name
- NCT00414271
- Testing
- Docetaxel, Capecitabine
- Where
- Singapore
- Volunteers
- 18 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Stage III Gastric Cancer, Stage IV Gastric Cancer
Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach Cancer
Phase II trial to study the effectiveness of bryostatin 1 and cisplatin in treating patients who have metastatic or unresectable stomach cancer.
- Trial name
- NCT00006389
- Testing
- bryostatin 1, cisplatin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Obesity
Metabolic Factors of Outcomes From Gastric Bypass Surgery
The objective of this study is to determine whether the metabolic, endocrine and energetic response to short term caloric restriction are factors in weight loss in subjects having gastric bypass (GB) surgery.
- Trial name
- Cassini (NCT01347840)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Ethicon Endo-Surgery
Gastro-Esophageal Junction Adenocarcinoma, Gastric Cancer
FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma
This is an open label, single-arm phase II, multi-institutional trial to evaluate the efficacy and safety of the combination of nab-paclitaxel and FOLFOX (FOLFOX-A) as first line therapy for patients diagnosed with…
- Trial name
- NCT03283761
- Testing
- Nab-paclitaxel 150 mg/m^2, Oxaliplatin 85 mg/m^2, 5-FU 1200 mg/m^2 x 2 D
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- Al B. Benson, III, MD
Semaglutide-Induced Gastric Motility, Gastroparesis
Body Surface Gastric Mapping in Patients on Semaglutide
Glucagon-like receptor-1 agonists (GLP-1 RAs), such as Semaglutide (Ozempic), are a class of drugs used for glycemic control in diabetes, and for weight loss and management in obesity.
- Trial name
- NCT06401746
- Testing
- Gastric Alimetry
- Where
- Australia
- Volunteers
- 9 people
- Sponsor
- University of Western Sydney
Obesity
Use of Radiofrequency Ablation for RGB Salvage
The present study will assess the feasibility of using endoscopic radiofrequency ablation (RFA) to treat the gastric pouch and stoma with the intent to cause tissue contraction and decreased compliance after a failed Roux-en-Y…
- Trial name
- NCT01910688
- Testing
- RFA treatment
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Medtronic - MITG
Gastric Cancer
FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer
This clinical study is a Phase 2, open-label study to assess the efficacy, safety profile of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer.
- Trial name
- NCT04768686
- Testing
- FLX475, Pembrolizumab
- Where
- 10 sites in South Korea
- Volunteers
- 20 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Gastroparesis
Placebo Controlled Trial of Botulinum Toxin for Gastroparesis
It is hypothesized that in some patients with gastroparesis increased pyloric tone may be a contributing feature. Botox relaxes the pylorus so that food can empty the stomach more rapidly.
- Trial name
- NCT00372970
- Testing
- Botulinum toxin A
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Temple University
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
Drugs used in chemotherapy such as cisplatin and fluorouracil use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach
- Trial name
- NCT00064259
- Testing
- oblimersen sodium, cisplatin, fluorouracil
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Gastric Cancer
Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy
The study is testing an intervention of an investigator-developed chemotherapy dose adjustment algorithm. The primary objective of this study is to evaluate the effectiveness of the chemotherapy dose adjustment algorithm for…
- Conditions
- Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Ampullary Cancer
- Trial name
- NCT04526886
- Testing
- Algorithm for cytopenia-related delay and dose-reduction of mFOLFOX chemotherapy
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Dumping Syndrome
Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome
multi-center, phase II study evaluating efficacy, safety and pharmacokinetics of pasireotide in patients with dumping syndrome
- Trial name
- NCT01637272
- Testing
- SOM230
- Where
- 17 sites in United States, Belgium and 3 more
- Volunteers
- 43 people
- Sponsor
- Novartis Pharmaceuticals
Gastric Cancer
A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.
This study will assess the safety and efficacy of Xeloda, given in combination with standard chemotherapy regimens, for the first-line treatment of advanced and/or metastatic gastric cancer.
- Trial name
- NCT00454636
- Testing
- Cisplatin, Capecitabine, Epirubicin
- Where
- 51 sites in Spain
- Volunteers
- 158 people
- Sponsor
- Hoffmann-La Roche
Gastro-oesophageal Reflux Disease
Physical Activity and Gastrointestinal Investigations
This is an observational study, which aims to compare the outcomes of ambulatory gastrointestinal investigations with physical activity using accelerometry.
- Trial name
- NCT01507298
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- Imperial College London
Gastroparesis
Effect of Vibrant Capsule on Gastric Emptying and Antropyloroduodenal Motility in Healthy Volunteers
The Vibrant capsule is a novel vibrating device for the treatment of gastrointestinal disorders. The effect of different vibrations on the motor functions of the gastrointestinal tract are unclear.
- Trial name
- NCT02736799
- Testing
- Vibrant Capsule (1 vibration), Vibrant Capsule (3 vibration), Vibrant Capsule (5 vibration)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vibrant Ltd.
Metastatic Gastric Cancer, Metastatic Breast Cancer
Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects
The purpose of this clinical study is to assess the safety and tolerability and efficacy of active immunotherapy with dose escalation and cohort expansion of OBI-833 in advanced/metastatic gastric, lung, colorectal, or breast…
- Conditions
- Metastatic Gastric Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Lung Cancer
- Trial name
- NCT02310464
- Testing
- OBI-833/OBI-821
- Where
- 4 sites in Taiwan
- Volunteers
- 25 people
- Sponsor
- OBI Pharma, Inc